CAMBRIDGE, Mass--(BUSINESS WIRE)--Sep. 14, 2016--
WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company
focused on developing targeted therapies for patients impacted by rare
diseases, today announced that Paul Bolno, M.D., MBA, President and
Chief Executive Officer, will participate in a fireside chat and provide
a company overview at the Leerink Partners Rare Disease &
Immuno-Oncology Roundtable on Wednesday, September 28, 2016, at 9:00
A.M. ET in New York, NY.
About WAVE Life Sciences
At WAVE Life Sciences, we are driven by an unwavering passion and
commitment to deliver on our mission of confronting challenging diseases
by developing transformational therapies and empowering patients. We are
utilizing our innovative and proprietary synthetic chemistry drug
development platform to design, develop and commercialize stereopure
nucleic acid therapeutics that precisely target the underlying cause of
rare and other serious genetically defined diseases. Given the
versatility of our chemistry platform, WAVE’s deep, diverse pipeline
spans multiple modalities including antisense, exon-skipping, and
single-stranded RNAi. For more information, please visit www.wavelifesciences.com
and follow us on Twitter at @WAVELifeSci and LinkedIn.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160914005248/en/
Source: WAVE Life Sciences
Investor Contact:
WAVE Life Sciences
Jillian Connell,
617-949-2981
jconnell@wavelifesci.com
or
Media
Contact:
Feinstein Kean Healthcare
Jess Rowlands,
202-729-4089
jessica.rowlands@fkhealth.com
X
LinkedIn
Glassdoor
